Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today.

Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011.

CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. 


Biotechnology

Life Sciences

Medical Devices

Therapeutics

CCRM

Cynthia Lavoie

Jessica Bond

Anna Geva

Debra Wilson

Stacey Johnson

Michael Israels

Ravi Kher

Hong Chang

Sherif Sheta

Sven Kili

Jana MacHan

Cynthia Elias

The Leadership Team at CCRM is responsible for strategic oversight and direction in the development and commercialization of regenerative medicine technologies. Comprising experts in operations, finance, technology sourcing, and communications, this team collaborates to drive innovation, secure investments, and ensure effective transition of RM solutions from the lab to clinical application, ultimately aiming to fulfill the potential of cell and gene therapies in improving patient outcomes.

Leadership Team

Development and Quality Assurance Team

Operations Team

Leadership Team

About

Team members

Other teams at CCRM

Development and Quality Assurance Team

Operations Team